Samiya Rashid, DO
Neurology · Tahlequah, OKNPI 1831139682
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $38,743 of the $63,330 with a category attached, or 61.2%. SK Life Science, Inc. accounts for 66.6% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2020 at $30,266 and has fallen 99.8% since, to $63 in 2022.
Across 72 payments — averaging $879.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SK Life Science, Inc.$42K
- Greenwich Biosciences, Inc.$14K
- Neurelis, Inc.$7K
- Neurocrine Biosciences, Inc.$32
Across 23 payments — averaging $8159.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$138K
- Neurocrine Biosciences, Inc.$27K
- UCB, Inc.$22K
What the payments were for
- Consulting fees$19,30030%
- Speaking & faculty fees$38,74361%
- Travel & lodging$2,9745%
- Food & beverage$2,3134%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| SK Life Science, Inc. | 47 | $42,171 |
| Greenwich Biosciences, Inc. | 16 | $14,002 |
| Neurelis, Inc. | 8 | $7,125 |
| Neurocrine Biosciences, Inc. | 1 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XCOPRI$24,364
- Cenobamate$17,001
- Epidiolex$14,002
- VALTOCO$7,125
How this compares
$63,330 in reported general payments places this provider in the 85th percentile of 152 neurology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lacosamide | 16 | $1,708 |
| Acetazolamide ErAcetazolamide | 13 | $1,665 |
| Dalfampridine ErDalfampridine | 14 | $659 |
| Carbamazepine ErCarbamazepine | 15 | $648 |
| Memantine Hcl | 24 | $508 |
| Gabapentin | 30 | $451 |
| Nortriptyline Hcl | 31 | $450 |
| Levetiracetam | 34 | $425 |
| Zonisamide | 22 | $336 |
| Topiramate | 36 | $322 |
| Donepezil Hcl | 29 | $138 |
| Propranolol Hcl | 23 | $100 |
Paid to pharmacies, not to this prescriber.
Other neurology in Tahlequah
- Cherian KarunapuzhaOklahoma City$4.1M
- Gabriel PardoOklahoma City$1.5M
- Jaclyn DuvallTulsa$1.4M
- Gregory ConnorTulsa$444K
- Brett DeesNorman$420K
- Eduardo de SousaMoore$393K
- Tania ReynaTulsa$353K
- Marguerite ButcheeOklahoma City$324K
- Chelsea BerkleyOklahoma City$277K
- Baha Abu-EshehArdmore$230K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.